[+]

C & C -

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

	perwork Reduction Act of 1995, no	persons are required			ce; U.S. DEPARTMENT OF COMMERCE ss it displays a valid OMB control number.
The			Application Number	10/697,82	8
2008	TRANSMITTAL		Filing Date	October 29, 2003	
[ \vec{\vec{\vec{\vec{\vec{\vec{\vec{			First Named Inventor	ROSEN, S	STEVEN D.
EMARTE	FURIVI	FORM		1653	
	sed for all correspondence after initi	ial filing)	Examiner Name	MONSHIP	POURI, MARYAM
Total I	Number of Pages in This Submissio	on 12	Attorney Docket Number	UCAL-138	BDIV
		ENCLOSUR	ES (check all that apply)		
Amend Amend A  A  Extens  Expres	ransmittal Form  Fee Attached  dment / Reply  After Final  Affidavits/declaration(s)  sion of Time Request  ss Abandonment Request	(for an Drawin Licensi Petition Provisi Power	ing-related Papers  n to Convert to a onal Application of Attorney, Revocation e of Correspondence		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Petition for Certificate of Correction (2 pgs.)  Certificate of Correction (1 pg.)
Docum Respondence Incomp	ied Copy of Priority ments  Reconse to Missing Parts/		al Disclaimer st for Refund umber of CD(s	3.10.06 (	Other Enclosure(s) (please identify below):  Notice of Allowance dated (7 pgs.)  last page of Issue Patent (1 pg.)
Signing Attorney/A (Reg. No.) Signature	SIGNAT  Signat  BOZICEVIC, FIELD	52,581	ICANT, ATTORNEY, OF	COLUM S AGENT	orrection
Date September 5, 2006			· · · · · · · · · · · · · · · · · · ·	<del>of</del> C	01100.

EXPRESS MAIL LABEL NO. EV 686 489 752 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



# **Express Mail No. EV 686 489 752 US**

# PETITION FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322 FOR PATENT AND TRADEMARK OFFICE ERROR

Address to: Mail Stop DAC Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket Number	UCAL-138DIV		
First Named Inventor	STEVEN ROSEN		
Application Number	10/697,828		
Filing Date	October 29, 2003		
Patent Number	7,070,971		
Issue Date	July 4, 2006		
Title	GLYCOSYL		
	SULFOTRANSFERASES		
	GST-4α, AND GST-6		

Sir:

Applicants petition under 37 C.F.R. § 1.322 for a Certificate of Correction to correct errors in the claims for the above-identified patent due to Patent and Trademark Office error.

Transmitted herewith for filing is a Certificate of Correction for the above-identified patent. Please make the following corrections to Claim 1.

In Claim 1, column 247, line 34, please replace the word "75%" with the word -- 90% --.

Enclosed is a copy of the Notice of Allowance mailed on March 10, 2006, showing the Examiner's amendment of Claim 1 to recite 90% rather than 75%. Also enclosed, is a copy of the last page of the issued patent showing the incorrect language of the claims that resulted from Patent and Trademark Office error.

C/1. 20 0 1 100

USSN: 10/697,828 Atty Dkt: UCAL-138DIV

It is believed that no fee is due since the error was made by the Patent and Trademark Office. However, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. § 1.20 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: <u>Sept. 5, 2004</u>

Edward J. Baba

Registration No. 52,581

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, CA 94303

Telephone: (650) 327-3400 Fax: (650) 327-3231

F:\DOCUMENT\UCAL\138div\Certificate of Correction Petition UCAL-138.rtf

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,070,971 DATED : July 4, 2006

INVENTOR(S): Steven Rosen, Jin Kyu Lee, Stefan Hemmerich

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

In Claim 1, column 247, line 34, the word "75%" should be -- 90% --.

MAILING ADDRESS OF SENDER:

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200

East Palo Alto, CA 94303

PATENT NO: 7,070,971

No. of add'l copies @ 50¢ per page



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexendria, Virginia 22313-1450 www.uspto.gov

# NOTICE OF ALLOWANCE AND FEE(S) DUE

24353

7590

03/10/2006

BOZICEVIC, FIELD & FRANCIS LLP 1900 UNIVERSITY AVENUE SUITE 200 EAST PALO ALTO, CA 94303 EXAMINER

PAPER NUMBER

MONSHIPOURI, MARYAM

ART UNIT

DATE MAILED: 03/10/2006

. Έν Γ

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/697.828	10/29/2003	Steven D. Rosen	UCAL-138DIV	9294

TITLE OF INVENTION: NOVEL GLYCOSYL SULFOTRANSFERASES GST-4ALPHA, GST-4BETA, & GST-6

 APPLN. TYPE
 SMALL ENTITY
 ISSUE FEE
 PUBLICATION FEE
 TOTAL FEE(S) DUE
 DATE DUE

 nonprovisional
 NO
 \$1400
 \$300
 \$1700
 06/12/2006

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

Bozicevic, Field, & Francis

MAR 1 4 2006

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Page 1 of 3

Confirm PFA 4/10/06

Intr. Summary 4/10/06

IF Due 6/10/00 out 3/14/2

The colibit solutions

PTOL-85 (Rev. 01/06) Approved for use through 04/30/2007.



### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 vvvv.uspro.gev

APPLICATION NO.	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/697,828 10/29/2003		0/29/2003	Steven D. Rosen	UCAL-138DIV	9294
24353	7590	03/10/2006		EXAM	INER
		FRANCIS LLP		MONSHIPOUT	RI, MARYAM
1900 UNIVERS				ART UNIT	PAPER NUMBER
SUITE 200 EAST PALO AI	CTO, CA 9	94303		1653 DATE MAILED: 03/10/200	6

# Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OIPE 428		
SFL 0 2 2000 B	Application No.	Applicant(s)
· \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	10/697,828	ROSEN ET AL.
Notice of Adjantes lity	Examiner	Art Unit
	Maryam Monshipouri	1653
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS (herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT Richard of the Office or upon petition by the applicant. See 37 CFR 1.313  1. This communication is responsive to	OR REMAINS) CLOSED in this apport of the communication GHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
2. ☑ The allowed claim(s) is/are <u>1,31,32,36 and 37</u> .		•
3.  ☐ Acknowledgment is made of a claim for foreign priority un a) ☐ All b) ☐ Some* c) ☐ None of the:  1.  ☐ Certified copies of the priority documents have 2.  ☐ Certified copies of the priority documents have 3.  ☐ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONMITHIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitinformal patent APPLICATION (PTO-152) which give 5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must (a) ☐ including changes required by the Notice of Draftsperson 1) ☐ hereto or 2) ☐ to Paper No./Mail Date  (b) ☐ including changes required by the attached Examiner's Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the composition of the depose attached Examiner's comment regarding REQUIREMENT Foreign and the comment of the depose attached Examiner's comment regarding REQUIREMENT Foreign and the comment of the depose attached Examiner's comment regarding REQUIREMENT Foreign and the comment of the	been received.  been received in Application No cuments have been received in this report of this communication to file a reply of this communication to file a reply of this application.  Itted. Note the attached EXAMINER's reason(s) why the oath or declarate the submitted.  The submitted of the submitted	complying with the requirements  S AMENDMENT or NOTICE OF tion is deficient.  948) attached  ffice action of the back) of the back of the submitted. Note the
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date	6. ☑ Interview Summary Paper No./Mail Date B), 7. ☑ Examiner's Amendre	e Filed 3/1/06

Serial Number: 10/697,828

Art Unit 1653

An **Examiner's Amendment** to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Ms. Paula A. Borden on 3/2/2006.

## **Examiner's Amendment to the Claims**

Cancel claims 2, 5-30, 33-35, 38-39.

In claim 1, line 3, after "at least about ", delete "75%", and substitute therefor --- 90% ---.

In claim 1, line 4, after "SEQ ID NO:8", insert --- wherein said GST polypeptide exhibits N-acetyl glucosamine-6-O-sulfotransferase activity ---.

In claim 36, line 1, delete "claim 34" and substitute therefor --- claim 1 ---.

In claim 37, line 1, delete "claim 34" and substitute therefor --- claim 1 ---.

# **Examiner's Amendments to the Specification**

In page 1, underneath the title insert the following:

---- This application is a Divisional of U.S. Application No. 09/593,828 filed 6/13/2000, now U.S. Patent No. 6,852,528 issued 2/8/2005, which claims priority to U.S. Provisional Application No. 60/144,694, filed 7/20/1999. ---.

The following is an **Examiner's Statement of Reasons for Allowance**:

Claims 1, 31-32, 36-37 are directed to a glycosyl sulfotranferase (GST) of specific amino acid composition and specifically claimed homologs thereof with the same activity. Claimed GST polypeptides (i.e. full length polypeptide and its mentioned

Serial Number: 10/697,828

Art Unit 1653

homologs) are free of prior art. Further, the prior art does not teach or suggest preparing such specifically claimed products. Hence said products are also non-obvious.

Claims 1, 31-32, 36-37 are allowed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maryam Monshipouri whose telephone number is (571) 272-0932. The examiner can normally be reached on 7:00 a.m to 4:30 p.m. except for alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Weber Jon P. can be reached on (571) 272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Maryam Monshipouri Ph.D.

Primary Examiner

\*\*\*

(O' "&)						
SEP O 5 2006 B	Application No.	Applicant(s)				
	10/697,828	ROSEN ET AL.				
Examiner-Initiated Interview Summary	Examiner	Art Unit				
	Maryam Monshipouri	1653				
All Participants:	Status of Application:	_				
(1) <u>Maryam Monshipouri</u> .	(3)					
(2) <u>Ms. P. A. Borden</u> .	(4)	(4)				
Date of Interview: 1 March 2006	Time:					
Type of Interview:  ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applic  Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description:	ant's representative)					
Part I.						
Rejection(s) discussed: 112 first paragraph,						
Claims discussed: 1-2, 30, 34-36		,				
Prior art documents discussed:						
Part II.						
SUBSTANCE OF INTERVIEW DESCRIBING THE GENE See Continuation Sheet	ERAL NATURE OF WHAT WA	S DISCUSSED:				
Part III.						
<ul> <li>☑ It is not necessary for applicant to provide a separate directly resulted in the allowance of the application. The of the interview in the Notice of Allowability.</li> <li>☑ It is not necessary for applicant to provide a separate did not result in resolution of all issues. A brief summa</li> </ul>	ne examiner will provide a writh record of the substance of the	ten summary of the substance interview, since the interview				
(Examiner/SPE Signature) (Applicar	nt/Applicant's Representative S	ignature – if appropriate)				

Continuation of Substance of Interview including description of the general nature of what was discussed: lack of enablement issues and written description issues directed to said claims were discussed. The examiner requested increasing percentage identity in claims 1-2 and 34-36 and reciting function in said claims. Ms. Borden agreed with the proposed changes to the claims and gave authority to the examiner to amend the claims in an Examiner's amendment.

#### -continued

ttggtccagg	atacaaaact	teacttgeaa	aacatccatc	tacatqaaac	cagtaggagt	2820
aaactggccc	aatattttac	aactaataag	gacaaaaagc	gaaaattaaa	aagaagggag	2880
tctttgcaag	atcaaagaag	tagaataaaa	ggaccatttg	atagagatgc	tgaatatatt	2940
agggctttaa	gaagacacct	tgtttattac	ccaagtgcac	gtcctgtgct	cagcttaagt	3000
agtggtagct	ggacattgaa	gcttcatttt	tttcaggaag	ttttaggaac	ttcaatgcgg	3060
gcattgtaca	tagtaagaga	ccctcgagct	tggatctatt	cagtgctata	tggtagtaaa	3120
ccaagtcttt	attctttgaa	gaatgtacca	gagcacttag	caaaattgtt	taaaatagag	3180
gaaggtaaaa	gcaaatgtaa	ttcgaattct	ggctatgctt	ttgagtatga	atcactgaag	3240
aaagaattag	aaatatccca	atcaaatgct	atctccttat	tatctcattt	gtgggtagca .	3300
aacactgcag	cageettgag	aataaataca	gatttgctgc	ctaccaatta	ccatctggtc	3360
aagtttgaag	atattgttca	ttttcctcag	aagactactg	aaaggatttt	tgctttcctt	3420
ggcattcctt	tgtctcctgc	tagtttaaac	caaatgctat	ttgccacttc	cacaaacctt	3480
ttttatcttc	catatgaggg	ggaaatatca	ccatctaata	ctaatatttg	gaaaacaaac	3540
ttgcctagag	atgaaattaa	actaattgaa	aacatttgct	ggacactgat	ggatcatcta	3600
ggatatccaa	agtttatgga	ctaa				3624

#### What is claimed is:

- 1. A glycosyl sulfotransferase (GST) polypeptide present in other than its natural environment, wherein said GST polypeptide comprises an amino acid sequence having at least about \$\frac{15\%}{25\%}\$ amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:8 wherein said GST polypeptide exhibits N-acetyl glucosamine-6-O-sulfotransferase activity.
- 2. The GST polypeptide of claim 1, wherein said GST polypeptide comprises the amino acid sequence set forth in SEQ ID NO:8.
- 3. The GST polypeptide of claim 1, wherein said GST polypeptide catalyzes the transfer of a sulfate group from a donor compound to an acceptor compound.
- 4. The GST polypeptide of claim 1, wherein said polypeptide is encoded by a nucleic acid comprising a nucleotide sequence having at least about 90% nucleotide sequence identity to SEQ ID NO:4.
- 5. The GST polypeptide of claim 1, wherein said polypeptide is encoded by a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO:4.

\* \* \* \* \*